India-based GVK Biosciences has unveiled a new brand, Clinogent, in the clinical development industry. Clinogent provides end-to-end clinical development services, from bioequivalence studies for generic pharma to late phase patient-based clinical studies. It offers solutions to complex data analysis and medical communication problems.
Clinogent is uniquely positioned as a comprehensive, full-service clinical development solutions organization offering end-to-end R&D solutions to pharma, generic, biotech and academic institutions globally, with a focus on the U.S., Europe and Asia. The launch of the new brand is a part of GVK Bio's growth plan to take the organization to the next level and creating a benchmark in the industry.
The Clinogent brand reflects the company's focus on further strengthening its operational expertise, talent and technology to evolve into a specialist and a comprehensive service provider. Clinogent is a constructed word that implies "innovative and intelligent clinical development solutions organization."
"Clinogent will be able to address the clinical needs of both innovator bio-pharmaceutical and generics companies worldwide,” said Manni Kantipudi, CEO of GVK Bio.